News articles about Viveve Medical (NASDAQ:VIVE) have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Viveve Medical earned a coverage optimism score of 0.09 on Accern’s scale. Accern also gave media headlines about the company an impact score of 44.584331523159 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the media headlines that may have impacted Accern Sentiment’s scoring:
VIVE has been the topic of several research analyst reports. Mizuho reissued a “buy” rating and set a $10.00 price target on shares of Viveve Medical in a report on Friday, January 5th. Ladenburg Thalmann Financial Services reissued a “buy” rating on shares of Viveve Medical in a report on Thursday, January 4th. Cowen set a $11.00 target price on Viveve Medical and gave the stock a “buy” rating in a report on Monday, October 23rd. ValuEngine raised Viveve Medical from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Finally, Northland Securities initiated coverage on Viveve Medical in a report on Friday, January 5th. They issued an “outperform” rating and a $8.00 target price on the stock. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $10.00.
Viveve Medical (VIVE) opened at $4.46 on Friday. Viveve Medical has a twelve month low of $3.30 and a twelve month high of $11.16. The company has a market capitalization of $137.90, a price-to-earnings ratio of -2.06 and a beta of -0.79. The company has a quick ratio of 3.63, a current ratio of 3.89 and a debt-to-equity ratio of 2.72.
COPYRIGHT VIOLATION WARNING: This piece was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/18/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-viveve-medical-vive-share-price.html.
About Viveve Medical
Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.
Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.